Seeking Alpha

Genprex up 29% on license for diabetes gene therapy

|About: Genprex, Inc. (GNPX)|By: , SA News Editor

Nano cap Genprex (GNPX +28.6%) is up on more than double normal volume in reaction to its agreement with the University of Pittsburgh for exclusive rights to a gene therapy for the potential cure of type 1 and type 2 diabetes.

The gene therapy acts by reprogramming alpha cells in the pancreas into beta-like cells, restoring their function and increasing insulin levels.

The company plans to pursue development partners globally.

Financial terms are not disclosed.